Eleven Bio is looking to come back to life after being on life support for much of 2016 with a merger deal combining it with Canadian company Viventia, who…

To any other private biotech, sinking $110 million into a custom-built manufacturing facility while its most advanced programs are in Phase II would be…

Mast was down by more than 80% premarket this morning on the news that its late-stage sickle cell disease candidate vepoloxamer (MST-188) failed to beat…

SV Life Sciences has joined with the VC wings of AbbVie and Merck KGaA to funnel $33.2 million into a DNA damage repair startup.

FierceBiotech talked with Sarepta interim CEO Ed Kaye about the historic approval of its DMD drug, and whether this decision marks a major turning point in…

On the back of a number of deals in recent months, mainly in dermatology and after dodging its own $100 billion-plus consumption by Pfizer this year, Allergan…

Swedish startup BioArctic has added AbbVie to a partnership roster that already includes another major biopharma, Eisai.

Teva will pay $250 million to help finish off mid-to-late stage work and then team up on selling Regeneron's experimental NGF antibody fasinumab.

Johnson & Johnson’s Janssen Pharmaceuticals has added to an existing partnership with the long-beleaguered Geron.